poorly understood. Future work is needed to understand how Epo treatment influences venous thromboembolism in myeloma and to identify patients at higher risk for this complication.
Although protocols of profound T-cell depletion and infusion of high doses of CD34 þ cells permit to reach engraftment without graft-versus-host disease in the vast majority of Haplo-HSCT recipients, 2 these patients experience a significant delay in immune reconstitution, leading to a high incidence of opportunistic infections. 3 The absence of the T-cell-mediated graft-versus-leukemia (GVL) effect has also been thought to render the recipients of a T-cell-depleted allograft from an HLA-Haplo relative more susceptible to leukemia relapse.
However, fundamental studies on Haplo-HSCT showed that a potent GVL effect could be mediated by natural killer (NK) cells when an HLA-disparate, NK-alloreactive relative was employed as a donor. 4 Although some reports indicated an association between poor clinical outcome and low lymphocyte counts early after Haplo-HSCT, 5 there is no study directly addressing the impact of T-cell reconstitution on relapse in longitudinal cohorts of pediatric patients having received this type of allograft. This issue is particularly relevant as the development of a potent immunity towards newly encountered antigens, including many of the known tumor antigens, requires thymic generation of naïve T cells with a broad specificity. 6 In view of these considerations, we decided to investigate the recovery of thymic function in 33 patients given Haplo-HSCT, including 27 treated for hematological malignancies, using signal joint (sj) and beta T-cell receptor excision circles (TRECs). 7, 8 These tools have already shown to be able to provide useful information in studies addressing the issues of aging, HIV infection and HSCT 9 but not yet in the context of the risk of leukemia relapse after HSCT. Table 1 . No patient received post-transplantation pharmacological immune suppression. The study was approved by the Ethical Committee of Fondazione IRCCS Policlinico San Matteo (approval number 446/DG).
Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) using the QIAamp DNA Blood Minikit (Qiagen, Hilden, Germany). Quantification of sj TREC and beta TREC was performed by real-time quantitative PCR (ABI PRISM 7500, Applied Biosystems, Foster City, CA, USA), as previously described. 10 Before the allograft, the median number of sj TREC/150 000 PBMC was 1375 (range 0 --27 612); it dropped to a median number of 27 (0 --1973) sj TREC/150 000 PBMC 3 months after the allograft. These numbers almost reverted to pre-transplantation levels at month 6, the value being 281 (0 --31 286) sj TREC/150 000 PBMC. Beta TREC copy numbers followed the same pattern (data not shown). Moreover, at each time point, sj TREC highly correlated with beta TREC (r ¼ 0.66, Po0.001, Pearson's correlation). As the TREC copy number per PBMC could be influenced by the proliferation of memory or effector T cells, we also expressed sj TREC and beta TREC counts/ml of patient blood taking advantage of the absolute cell counts. The total numbers of sj TREC and beta TREC displayed the same pattern as the numbers of TREC/150 000 PBMC (data not shown), ruling out an indirect effect of homeostatic T-cell proliferation in a lymphopenic host.
Among the 27 patients treated for malignancies, 8 relapsed at a median time of 7 months after transplantation (range 1.6 --18 months). With a 4-year median follow-up of the whole transplant population, patients who relapsed had significantly lower sj TREC values than the relapse-free patients both before transplantation (P ¼ 0.030) and at the different time points analyzed after the allograft (P ¼ 0.013 and 0.019, at 3 and 6 months, respectively) ( Figure 1a) . Also levels of beta TREC before transplantation Figure 1 . A low thymic function is associated with a high relapse risk. Mean (±s.e.) number of log10 sj TREC/blood (ml) (a) and beta TREC/ blood (ml) (b), before, 3 and 6 months after transplantation in patients with hematological malignancies that received a T-cell-depleted haplo-HSCT. Patients who experienced relapse were represented with black dotted lines, whereas patients maintaining complete remission with plain gray lines. Cumulative incidence of relapse in patients affected by malignant disorders who did or did not have detectable beta TREC before (c) and at month 6 after graft (d). Three patients relapsed before 6 months and were therefore excluded from the analysis at this time point.
and, even more significantly, at month 6 ( Figure 1b) were lower in patients who subsequently relapsed (P ¼ 0.026 and 0.013, respectively).
To further evaluate the role of thymic-dependent T-cell reconstitution on leukemia recurrence, we calculated the cumulative incidence of relapse subdividing patients into two groups, that is, those with a detectable thymic function and those without any thymic function. The cut-offs chosen were based on the detection sensitivity of the TREC assays employed, that is, sj and beta TREC o0.1 and 0.01/150 000 PBMC, respectively. This was determined for TREC values before transplantation and those at month 6, because values at month 3 were too low to define this cut-off reliably. Absence of detectable sj TREC at each time point corresponded to an increased incidence of relapse without this reaching statistical significance (data not shown). More notably, the lack of detectable beta TREC before and at month 6 after the allograft was strongly associated with a higher incidence of relapse (P ¼ 0.011 and 0.014, respectively) (Figures 1c and d) . Use of median sj or beta TREC value as a cut-off gave similar results (data not shown). We also tested other parameters that have been shown to influence relapse rate, but neither age (P ¼ 0.28), high-risk disease (P ¼ 0.73), conditioning regimen (P ¼ 0.24) or NK-cell alloreactivity (P ¼ 0.13), nor the number of CD34 þ cells infused (P ¼ 0.72) had a statistically significant impact on relapse in univariate analysis in this relatively small cohort of patients.
An influence of pre-transplantation thymic function on outcome has already been observed, both in adults 11 and children. 12 We show herein that thymic function could affect immune responses to malignant cells. Although, overall, the quality of immune reconstitution after allo-HSCT is associated with outcome of the patient, 13 the specific impact on leukemia relapse of thymicdependent neo-generation of T cells has not been thoroughly investigated. The correlation existing between low beta TREC value at month 6 after transplantation and leukemia recurrence provides mechanistic insights, indicating that an ongoing thymic differentiation of naïve T cells endowed with anti-leukemia potential could be crucial in preventing relapse and mediating GVL. To the best of our knowledge, after allo-HSCT, only a single study described reduced sj TREC levels at the time of cytogenetic relapse compared with pretransplantation level in a small cohort of adult patients with chronic myeloid leukemia.
14 Because we found a stronger correlation between the lack of detectable beta TREC and disease recurrence, this finding emphasizes the link between early intrathymic differentiation and leukemia relapse.
In conclusion, this study sheds a new light on the impact and mechanisms of thymic dysfunction on the GVL effect in pediatric patients. This further emphasizes the importance of preserving and rebuilding an effective thymic function after allogeneic HSCT. Use of agents able to preserve function of thymic epithelial cells, such as keratinocyte growth factor, or of cytokines having a crucial role in T-cell homeostasis and differentiation, such as IL-7, can be of particular interest in this perspective. 9, 15 
